Raphael Pharmaceutical (RAPH) Capital Expenditures (2024)
Raphael Pharmaceutical's (RAPH) quarterly Capital Expenditures came in at $1000.0 in Q1 2024.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Capital Expenditures (2024) Analysis & Trends
Raphael Pharmaceutical has disclosed Capital Expenditures across 1 years of filings, most recently posting $1000.0 for Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |